Security key
29286M113
enGene Therapeutics Inc. - *W EXP 10/31/202 (ENGNW)
CUSIP: 29286M113
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / *W EXP 10/31/202
- Total 13F shares
- 4,845,358
- Total 13F value
- $13,909,444
- Share change
- +266,881
- SEC-reported price per share
- $2.96
- Number of holders
- 14
- Value change
- +$1,124,531
- Number of buys
- 3
- Number of sells
- 8
Report period
Q4 2025
Institutions
14
Top holders
10
ENGNW full security history
Ownership snapshot
Full 13F holder table
enGene Therapeutics Inc. SEC filings
enGene Therapeutics Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of ENGNW - enGene Therapeutics Inc. - *W EXP 10/31/202 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Deep Track Capital, LP
Disclosed value leader
FCPM III SERVICES B.V.
Comparable rows
5/15
Latest evidence
11 Nov 2025
13D/G
13F
3/4/5
Lead comparable stake: 6.7%
10 rows are not safely comparable across share classes.
13D/G row: Deep Track Capital, LP
Showing 1-6 of 15 holder rows.
Quick read
Deep Track Capital, LP leads the comparable SEC ownership view at 6.7%.
5 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Deep Track Capital, LP's linked filing trail.
Comparable ownership
Top 5
Deep Track Capital, LP
6.7%
Fonds de solidarite des travaille...
4.5%
Adage Capital Management, L.P.
3%
Kynam Capital Management, LP
2.2%
BIOTECHNOLOGY VALUE FUND L P
1.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Deep Track Capital, LP |
13D/G
13F
Company
|
6.7%
Reported 13D/G
· 11 Nov 2025
|
$30,048,631
4,317,332 shares
|
+$14,462,734 | 11 Nov 2025 |
| Fonds de solidarite des travailleurs et des travailleuses du Quebec |
3/4/5
13D/G
10%+ Owner
|
4.5%
Reported 13D/G
· 30 Sep 2024
|
$45,542,295
3,036,153 shares
|
— | 18 Apr 2024 |
| Adage Capital Management, L.P. |
13D/G
|
3%
Reported 13D/G
· 31 Dec 2024
|
$6,115,072
1,528,768 shares
|
$0 | 31 Dec 2024 |
| Kynam Capital Management, LP |
13F
13D/G
Company
|
2.2%
Reported 13D/G
· 31 Dec 2025
|
$34,109,635
4,994,090 shares
|
— | 30 Sep 2025 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
1.8%
Reported 13D/G
· 27 Jan 2025
|
$3,781,608
945,402 shares
|
-$8,424,148 | 27 Jan 2025 |
| Forbion Growth Opportunities Fund I Cooperatief U.A. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$60,505,422
6,798,362 shares
|
— | 30 Oct 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
14
Shares
4,845,358
Rows available
14
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
17
Q4 2025 holders
14
Holder diff
-3
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|